Alberta Blue Cross® has released its annual drug pipeline report, highlighting breakthrough therapies and expanding GLP-1 use as key future drivers of rising private plan costs. While clinical innovation continues to deliver meaningful advances for Canadians, it’s also expected to influence the financial landscape for plan sponsors.
“Health benefits have become a crucial part of employee attraction and retention, and a way for organizations to show they care. Each year, clinical innovation leads to breakthrough treatments and specialty medications that have the potential to improve employee health and wellbeing. Employers will need to plan proactively as costs and utilization continue to grow,” says Margaret Wurzer, director, Benefits Design and Strategy at Alberta Blue Cross.
The 2026 drug pipeline report provides the most current and relevant look at emerging medications, including new drugs, expanded indications and trends that may impact drug plans. Fortunately, generic and biosimilar pipelines remain robust, with associated cost savings. These cost savings, however, won’t be sufficient to offset the anticipated continued increases in drug spend.
Key trends shaping 2026
The 2026 report identifies several developments expected to influence employer-sponsored drug plans.
- Advances in women’s health, with a second non-hormonal treatment for menopausal symptoms and the first targeted therapy for postpartum depression were approved in Canada.
- Ongoing cost pressures from GLP-1 therapies, as expanded uses beyond diabetes and obesity, and future launches of more effective and convenient dosage forms of GLP-1 medications, will continue to drive growing demand.
- More options for chronic, high-prevalence respiratory and skins conditions including expanded biologic uses, a new treatment for chronic hand eczema and an intranasal epinephrine option.
- Emerging neurologic therapies, including a disease-modifying Alzheimer’s treatment that will require new health-care processes and a potential new option for progressive MS now under Health Canada review.
- High-profile generics and biosimilars are under review by Health Canada which may offset some cost pressures and create opportunities for plan sustainability.
The full report is available here.
About the drug pipeline report
For the 2026 report, Alberta Blue Cross reviewed more than 440 new drug and supplemental submissions that were made to Health Canada in 2025. From this broader list, they selected the drugs with the highest potential relevance to private plans.
About Alberta Blue Cross
As the largest provider of health benefits in Alberta, we believe we have the potential and responsibility to impact people’s lives for the better. We believe all communities should thrive, and we are committed to serving as a champion for wellness by promoting the health of Albertans.
For more information, please contact Jaclyn Spurrell, manager, Corporate Communications at Alberta Blue Cross at jspurrel@ab.bluecross.ca.
The media release was shared as a news story on:
Benefits and Pensions Monitor on GLP‑1 boom strains employer drug plans while generics trail behind: report
